Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase

References

• Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805–43
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22–9
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2008;300:555–70
   PubMed Web of Science ®Google Scholar
• Tronchet JM, Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr Top Med Chem 2003;3:1496–511
   PubMed Web of Science ®Google Scholar
• Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008;15:1083–95
   PubMed Web of Science ®Google Scholar
• De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153–79
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2013;33:E1–72
   PubMed Web of Science ®Google Scholar
• Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724
   PubMed Web of Science ®Google Scholar
• Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475–84
   PubMed Web of Science ®Google Scholar
• Mansky LM. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 1996;222:391–400
   PubMed Web of Science ®Google Scholar
• Kirschberg TA, Balakrishnan M, Huang W, et al. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase – structure-activity relationships and crystallographic analysis. Bioorg Med Chem Lett 2008;18:1131–4
   PubMed Web of Science ®Google Scholar
• De La Rosa M, Kim HW, Gunic E, et al. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006;16:4444–9
   PubMed Web of Science ®Google Scholar
• Muraglia E, Kinzel OD, Laufer R, et al. Tetrazolethioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg Med Chem Lett 2006;16:2748–52
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg Med Chem 2009;17:5920–7
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2009;17:5775–81
   PubMed Web of Science ®Google Scholar
• Zhan P, Wang L, Liu H, et al. Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch Pharm Res 2012;35:975–86
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu B, Kuhen KL, et al. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2006;16:4174–7
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Cao Y, et al. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2008;18:5368–71
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Stoehr A, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother 2010;54:3170–8
   PubMedGoogle Scholar
• Zhan P, Li D, Chen X, et al. Functional roles of azoles motif in anti-HIV agents. Curr Med Chem 2011;18:29–46
   PubMed Web of Science ®Google Scholar
• Leung CS, Zeevaart JG, Domaoal RA, et al. Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. Bioorg Med Chem Lett 2010;20:2485–8
   PubMed Web of Science ®Google Scholar
• Zeevaart JG, Wang L, Thakur VV, et al. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. J Am Chem Soc 2008;130:9492–9
   PubMed Web of Science ®Google Scholar
• Mislak AC, Frey KM, Bollini M, et al. A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Biochim Biophys Acta 2014;1840:2203–11
   PubMed Web of Science ®Google Scholar
• Siwek A, Wujec M, Stefanska J, Paneth P. Antimicrobial properties of 4-aryl-3-(2-methyl-furan-3-yl)-Δ2-1,2,4-triazoline-5-thiones. Phosphorus Sulfur Silicon Relat Elem 2009;184:3149–59
   Web of Science ®Google Scholar
• El-Ashmawy MB. The reaction of 3-(2-thienyl)-5-mercapto-4H-1,2,4-triazole with aryl halides. Mansoura J Pharm Sci 1991;7:168–77
   Google Scholar
• Malbec F, Milcent R, Barbier G. Derivatives of 2,4-dihydro-1,2,4-triazole-3-thione and 2-amino-1,3,4-thiadiazole from thiosemicarbazones of esters. J Heterocycl Chem 1984;21:1689–98
   Web of Science ®Google Scholar
• Benno R, Hildegard B. Splitting of hexamethylenetetramine addition compounds of N-haloacetylated substituted anilines be means of sulfur dioxide. Pharmazie 1949;4:149–50
   Google Scholar
• Xie H, Ng D, Savionv SN, et al. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J Med Chem 2007;50:4898–908
   PubMed Web of Science ®Google Scholar
• Geitmann M, Unge T, Danielson H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem 2006;49:2367–74
   PubMed Web of Science ®Google Scholar
• Elinder M, Selhorst P, Vanham G, et al. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism – importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol 2010;80:1133–40
   PubMed Web of Science ®Google Scholar
• Frączek T, Siwek A, Paneth P. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs. J Chem Inf Model 2013;53:3326–42
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
   PubMed Web of Science ®Google Scholar
• Glide, version 5.7. New York, NY: Schrödinger, LLC; 2011
   Google Scholar
• Girardet JL, Koh YH, de la Rosa M, et al. S-triazole alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase. US patent 7947721 B2, May 24, 2011
   Google Scholar
• Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995;2:303–8
   PubMedGoogle Scholar
• Schauer GD, Huber KD, Leuba SH, Sluis-Cremer N. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acid Res 2014;42:11687–96
   PubMed Web of Science ®Google Scholar
• Seckler JM, Leioatts N, Miao H, Grossfield A. The interplay of structure and dynamics: insights from a survey of HIV-1 reverse transcriptase crystal structures. Proteins 2013;81:1792–801
   PubMed Web of Science ®Google Scholar